

Vantage Radiology is pleased to be offering PYLARIFY (piflufolastat F 18) for patients with suspected prostate cancer metastasis who are candidates for initial definitive therapy or suspected recurrence based on elevated PSA.



**Quick Facts about Pylarify:**

- Indicated for PET/CT imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
  - With suspected metastasis who are candidates for initial definitive therapy
  - With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level
- PET Imaging<sup>§</sup> has the potential to improve disease localization compared to standard imaging, thus enhancing therapeutic decision-making<sup>19,20,21</sup>

§ With an appropriate tracer and combined with CT or MRI.
- PSMA PET/CT can detect lesions between 4 mm and 8 mm, and therefore has a higher detection rate<sup>5,12</sup>
  - Because up to 80% of nodal metastases in PCa are smaller than 8 mm in size, PSMA PET/CT is a promising imaging modality<sup>5</sup>
- PSMA PET/CT is also effective at lower PSA levels; the rate of detection of nodal metastases has been reported to be 46% when PSA was <0.2 ng/mL<sup>5</sup>
- FDA approved
- CMS reimbursed

**Patient prep:** The patient will need to drink 20 oz of water to hydrate prior to the exam.

- Please advise the patient to come well-hydrated. Dehydration may affect the results of imaging.

**Important to note:** The patient will need to hold still for the entire scan time on the table which is approximately 40 minutes.

**How to order in Epic:** Search - PET CT Prostate; IMG4054 – PET CT Prostate Base of Skull to Mid Thigh

Please call with any questions or concerns.

Sincerely,  
**Naomi Davidson, DO, MBA**  
PET Medical Director  
253.661.4755

**PYLARIFY<sup>®</sup> achieved high PPV, specificity, and NPV compared to standard imaging while maintaining comparable sensitivity<sup>2</sup>**

- PYLARIFY<sup>®</sup> PET/CT specificity was significantly higher than with standard imaging (97.9% vs 65.1%)
- PYLARIFY<sup>®</sup> PET/CT nearly tripled the PPV compared to standard imaging (86.7% vs 28.3%)
- PYLARIFY<sup>®</sup> PET/CT achieved similar sensitivity to standard imaging

**To obtain further information on PYLARIFY<sup>®</sup> please scan the QR code below.**



2. PYLARIFY<sup>®</sup> [package insert]. North Billerica, MA: Progenics Pharmaceuticals, Inc., a Lantheus company.  
 5. Alipour R, Azad A, Hofman MS. Guiding management of therapy in prostate cancer: time to switch from conventional imaging to PSMA/PET? *Ther Adv Med Oncol*. 2019;11:1-14. doi:10.1177/1758835919876828  
 12. Pienta KJ, Gorin MA, Rowe SP, et al. A phase 2/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET/CT with <sup>18</sup>F-DCFPYL in prostate cancer patients (OSPPEY) [published online ahead of print, February 26, 2021]. *J. Urol*. doi: 10.1097/JU.0000000000001698  
 19. Hofman MS, Lawrentschuk N, Francis RJ, et al; proPSMA Study Group Collaborators. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *Lancet*. 2020;395(10231):1208-1216. doi:10.1016/S0140-6736(20)30314-7  
 20. Rousseau E, Wilson D, Lacroix-Poisson F, et al. A prospective study on 18F-DCFPYL PSMA PET/CT imaging in biochemical recurrence of prostate cancer. *J Nucl Med*. 2019;60(11):1587-1593. doi:10.2967/jnumed.119.226381  
 22. Li R, Ravizzini GC, Gorin MA, et al. The use of PET/CT in prostate cancer. *Prostate Cancer Prostatic Dis*. 2018;21(1):4-21. doi:10.1038/s41391-017-0007-8